MY104316A - Deravatives substituted at methylamino nitrogen - Google Patents

Deravatives substituted at methylamino nitrogen

Info

Publication number
MY104316A
MY104316A MYPI88000629A MYPI19880629A MY104316A MY 104316 A MY104316 A MY 104316A MY PI88000629 A MYPI88000629 A MY PI88000629A MY PI19880629 A MYPI19880629 A MY PI19880629A MY 104316 A MY104316 A MY 104316A
Authority
MY
Malaysia
Prior art keywords
formula
substituted
deravatives
methylamino
nitrogen
Prior art date
Application number
MYPI88000629A
Inventor
Giorgio Caravatti Dr
Andreas Fredenhagen Dr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY104316A publication Critical patent/MY104316A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

N- SUBSTITUTED DERIVATIVES OF STAUROSPORINE OF THE GENERAL FORMULA @@(FORMULA 1)@@IN WHICH [STAU] REPRESENTS A RESIDUE OF THE PARTIAL FORMULA@@(FORMULA 2)[STAU]@@AND R REPRESENTS A HYDROCARBYL RADICAL R0 OR AN ACYL RADICAL AC, WHICH RADICALS PREFERABLY HAVE A MAXIMUM OF 30 CARBON ATOMS, AND SALTS OF COMPOUNDS OF THE FORMULA I HAVING SALT- FORMING PROPERTIES, ARE DISTINGUISHED AS SELECTIVE INHIBITORS OF PROTEINKINASE C. THEY ARE MANUFACTURED BY CONVENTIONAL ALKYLATION OR ACYLATION, RESPECTIVELY, OF STAUROSPORINE.
MYPI88000629A 1987-06-15 1988-06-09 Deravatives substituted at methylamino nitrogen MY104316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH224487 1987-06-15
CH144088 1988-04-19

Publications (1)

Publication Number Publication Date
MY104316A true MY104316A (en) 1994-03-31

Family

ID=25687663

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88000629A MY104316A (en) 1987-06-15 1988-06-09 Deravatives substituted at methylamino nitrogen

Country Status (20)

Country Link
EP (1) EP0296110B1 (en)
JP (1) JP2708047B2 (en)
KR (1) KR970001529B1 (en)
AT (1) ATE134375T1 (en)
AU (1) AU617324B2 (en)
CA (1) CA1337763C (en)
DE (1) DE3855015D1 (en)
DK (1) DK175507B1 (en)
ES (1) ES2083956T3 (en)
FI (1) FI89362C (en)
GR (1) GR3019064T3 (en)
HK (1) HK1003788A1 (en)
HU (1) HU201329B (en)
IE (1) IE70523B1 (en)
IL (1) IL86632A0 (en)
MY (1) MY104316A (en)
NO (1) NO170634C (en)
NZ (1) NZ225018A (en)
PT (1) PT87719B (en)
YU (1) YU115488A (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (en) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd Ucn-01 and production thereof
JP2766360B2 (en) * 1988-02-04 1998-06-18 協和醗酵工業株式会社 Staurosporine derivative
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
USRE36736E (en) * 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
DE3924538A1 (en) * 1989-07-25 1991-01-31 Goedecke Ag INDOLOCARBAZOL AND THEIR USE
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
WO1993007153A1 (en) * 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
EP0541486A1 (en) * 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclic conjugates
WO1993018771A1 (en) * 1992-03-24 1993-09-30 Asahi Kasei Kogyo Kabushiki Kaisha PLATELET AGGLUTINATION INHIBITOR CONTAINING STAUROSPORINE η-LACTAM DERIVATIVE
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994006799A1 (en) * 1992-09-21 1994-03-31 Kyowa Hakko Kogyo Co., Ltd. Thrombocytopenia remedy
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2355184T3 (en) 1993-01-28 2011-03-23 Boston Scientific Limited THERAPEUTIC INHIBITORS OF VASCULAR MUSCLE CELLS.
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
US6051221A (en) * 1993-07-09 2000-04-18 Glaxo Wellcome Inc. BRK protein tyrosine kinase and encoding nucleic acid
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
EP0711557A1 (en) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Base for formulating pharmaceutical agents
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69715862T2 (en) 1996-06-25 2003-04-10 Cephalon, Inc. USE OF A K-252A DERIVATIVE TO TREAT PERIPHERAL OR CENTRAL NERVOUS DISEASES AND EXCESSIVE CYTOKINE FORMATION
ATE278397T1 (en) 1997-03-31 2004-10-15 Boston Scient Ltd USE OF CYTOSKELETON INHIBITORS TO PREVENT RESTENOSIS
DK1131073T3 (en) * 1998-11-23 2004-02-02 Novartis Ag Use of staurosporine derivatives for the treatment of ocular neovascular diseases
LT3351246T (en) 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
SK14042003A3 (en) 2001-05-16 2004-05-04 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
NZ532136A (en) 2001-10-30 2006-08-31 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
CN101897662B (en) * 2002-07-23 2013-05-22 诺瓦提斯公司 Ophtalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
CL2004001120A1 (en) 2003-05-19 2005-04-15 Irm Llc COMPOUNDS DERIVED FROM AMINA REPLACED WITH HETEROCICLES, IMMUNOSUPPRESSORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT DISEASES MEDIATED BY LYMPHOCYTE INTERACTIONS, SUCH AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS, CANCER DISEASES.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007002415A (en) * 2004-08-31 2007-04-23 Novartis Ag Combined use of prame inhibitors and hdac inhibitors.
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
JP2009516671A (en) 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト Neuroendocrine tumor treatment using mTOR inhibitors
CA2746764A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
IL294514A (en) 2008-12-18 2022-09-01 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
RU2011129229A (en) 2008-12-18 2013-01-27 Новартис Аг NEW SALTS
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
IT202000004291A1 (en) * 2020-03-02 2021-09-02 Indena Spa PROCESS FOR THE PURIFICATION OF CARBAZOLIC INDOLE ALKALOIDS
CN112812129A (en) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 Novel crystalline form of midostaurin, process for its preparation and its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2766360B2 (en) * 1988-02-04 1998-06-18 協和醗酵工業株式会社 Staurosporine derivative

Also Published As

Publication number Publication date
CA1337763C (en) 1995-12-19
PT87719A (en) 1988-07-01
JPS6434989A (en) 1989-02-06
FI89362B (en) 1993-06-15
HUT47587A (en) 1989-03-28
NZ225018A (en) 1990-09-26
ATE134375T1 (en) 1996-03-15
DK324888D0 (en) 1988-06-14
YU115488A (en) 1989-12-31
IE881787L (en) 1988-12-15
NO882613D0 (en) 1988-06-14
KR890000494A (en) 1989-03-15
DK175507B1 (en) 2004-11-15
GR3019064T3 (en) 1996-05-31
DE3855015D1 (en) 1996-03-28
NO882613L (en) 1988-12-16
FI882808A (en) 1988-12-16
NO170634B (en) 1992-08-03
ES2083956T3 (en) 1996-05-01
FI89362C (en) 1993-09-27
FI882808A0 (en) 1988-06-13
PT87719B (en) 1992-10-30
EP0296110A3 (en) 1991-02-27
KR970001529B1 (en) 1997-02-11
NO170634C (en) 1992-11-11
HK1003788A1 (en) 1998-11-06
DK324888A (en) 1988-12-16
EP0296110A2 (en) 1988-12-21
HU201329B (en) 1990-10-28
AU1757188A (en) 1988-12-15
IE70523B1 (en) 1996-12-11
EP0296110B1 (en) 1996-02-21
AU617324B2 (en) 1991-11-28
IL86632A0 (en) 1988-11-30
JP2708047B2 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
MY104316A (en) Deravatives substituted at methylamino nitrogen
DK0379979T3 (en)
DE3170437D1 (en) 2-oxoazetidine derivatives, their production and use
MY130736A (en) Imidazo(4,5-c) pyridin-4-one derivatives
GR3003738T3 (en)
IE892428L (en) Use of imidazopyrazole derivatives as analgesics and¹anti-inflammatory agents
ZA862348B (en) Diamine derivatives